IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-04368126.html

The Impact on Big Pharma’s Production Model of Medicine Policies in a Context of Austerity in France and the UK

Author

Listed:
  • Philippe Abecassis

    (CEPN - Centre d'Economie de l'Université Paris Nord - UP13 - Université Paris 13 - USPC - Université Sorbonne Paris Cité - CNRS - Centre National de la Recherche Scientifique, ACT - Analyse des Crises et Transitions - LABEX ICCA - UP13 - Université Paris 13 - Université Sorbonne Nouvelle - Paris 3 - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité - Université Sorbonne Paris Nord - Université Sorbonne Paris Nord)

  • Nathalie Coutinet

    (CEPN - Centre d'Economie de l'Université Paris Nord - UP13 - Université Paris 13 - USPC - Université Sorbonne Paris Cité - CNRS - Centre National de la Recherche Scientifique, ACT - Analyse des Crises et Transitions - LABEX ICCA - UP13 - Université Paris 13 - Université Sorbonne Nouvelle - Paris 3 - CNRS - Centre National de la Recherche Scientifique - UPCité - Université Paris Cité - Université Sorbonne Paris Nord - Université Sorbonne Paris Nord)

Abstract

The austerity policies implemented by France and the United Kingdom since the 2008 crisis have led to a drastic rationalisation of health spending in both countries. This is especially true for spending on medicines, which is an important part of the health budget. Even though health policies in the two countries seem to be very different, given the specificities of each health system, this rationalisation has expressed itself through greater privatisation, a hardening of mechanisms for controlling the prices of the most expensive drugs and incentives to use the cheapest drugs when possible, such as generic drugs. The pharmaceutical industry has not suffered much from these measures. It first reacted, at least provisionally, by accepting to develop generic drugs. As of 2012, Big Pharma companies have started to implement a new model for producing innovation and highly expensive drugs, grounded in biotechnology and customised medicine. This strategy is based on highly outsourced industrial organisations which have allowed the industry to benefit from healthcare systems, to reduce risks and to make large profits.

Suggested Citation

  • Philippe Abecassis & Nathalie Coutinet, 2017. "The Impact on Big Pharma’s Production Model of Medicine Policies in a Context of Austerity in France and the UK," Post-Print hal-04368126, HAL.
    • Handle: RePEc:hal:journl:hal-04368126
    DOI: 10.4000/osb.1935
    Note: View the original document on HAL open archive server: https://hal.science/hal-04368126v1
    as

    Download full text from publisher

    File URL: https://hal.science/hal-04368126v1/document
    Download Restriction: no
    File URL: https://libkey.io/10.4000/osb.1935?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Keywords

    ;
    ;
    ;
    ;
    ;
    ;
    ;

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-04368126. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.